InnoCare Pharma Initiates Phase 1 Clinical Trial for Novel Bispecific Antibody in Autoimmune Diseases

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-30
Category: health
Source: Markets Insider (via GlobeNewswire)

InnoCare Pharma has dosed the first subject in a Phase 1 clinical trial for ICP-B161, a bispecific antibody targeting TL1A and IL-23p19. This novel therapy is being developed for autoimmune diseases, including inflammatory bowel disease (IBD), and is designed with an extended half-life.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai